Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
CHU Caen Service de Pneumologie ( Site 0401)(0.0 mi away)Contact
+150 other location
This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib
(E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer
(NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with
one prior anti-PD-1/PD-L1 monoclonal antibody (mAb). The primary hypotheses of this study are
that pembrolizumab + lenvatinib (compared with docetaxel) prolongs: 1) overall survival (OS);
and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version
1.1 (RECIST 1.1) based on blinded independent central review (BICR).
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.